Motley Fool1d agoneutral
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity TrialsNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Simply Wall St.1d agoneutral
Hims & Hers Stock After Lilly Weight Loss Drug Deal Has The Bull Case Changed?Simply Wall St.1d agoneutral
Hims & Hers Health (HIMS) Adds FDA Approved Obesity Drugs To Its PlatformMotley Fool2d agoneutral
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the EvidenceSimply Wall St.2d agoneutral
Eli Lilly (LLY) Highlights ACR Data, Is The Stock Still 8% Undervalued?Barrons.com2d agoneutral
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly AgreementInvestorsHub2d agoneutral
Eli Lilly Partners With Hims & Hers to Expand Access to Obesity Treatments Through TelehealthMT Newswires2d agoneutral
Eli Lilly, Hims & Hers Health Expand Patient Access to Zepbound, FoundayoBusiness Wire2d agoneutral
Lilly and Hims & Hers expand access to FDA-approved Lilly medicinesGuruFocus.com2d agoneutral
State Street Health Care SPDR (XLV) Adds Eli Lilly and J&J on Nov. 4